Rarely does India Inc wake up and decide to go shopping abroad with conviction. So, when Sun Pharma acquired New Jersey-based pharma major Organon for $11.75 bn, in a deal expected to close in early 2027, it feels more like a declaration rather than a transaction.
For years, Indian companies have flirted with the idea of becoming global MNCs. They have opened offices abroad, hired consultants with reassuring accents, and printed 'global footprint' on annual reports. But true globalisation is not achieved through airport lounges and LinkedIn updates. It's achieved through ownership of assets, brands, markets - and, sometimes, challenges in unfamiliar time zones.
